WO1998016265B1 - Liquid embolic agents containing partially hydrolyzed polyvinyl acetate - Google Patents
Liquid embolic agents containing partially hydrolyzed polyvinyl acetateInfo
- Publication number
- WO1998016265B1 WO1998016265B1 PCT/US1997/018582 US9718582W WO9816265B1 WO 1998016265 B1 WO1998016265 B1 WO 1998016265B1 US 9718582 W US9718582 W US 9718582W WO 9816265 B1 WO9816265 B1 WO 9816265B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- occludant
- new
- precursor composition
- partially hydrolyzed
- radio
- Prior art date
Links
Abstract
This relates to a composition of matter comprising partially hydrolyzed polyvinyl acetate solutions suitable for use as embolic agent precursors. In addition, a procedure for introducing the solutions into the human body to form precipitated embolic occlusion masses is shown. Finally, a procedure for treatment of hepatic tumors using portal vein embolism is described.
Claims
1. An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, b.) a pharmaceutically acceptable solvent, and c.) a soluble radio-opaque material.
2. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10.000 to 500,000.
3. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50.000 to 100,000.
4. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
5. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
6. The occludant precursor composition of claim 5 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
20
7. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises ethanol.
8. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
9. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
10. The occludant precursor composition of claim 9 wherein the aqueous ethanolic solution contains 45-55% (vol) ethanol.
1 1. [cancelled]
12. The occludant precursor composition of claim 1 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
13. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises iopromide.
14. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises metrizamide.
15. A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate. [and] ii.) a pharmaceutically acceptable solvent, iii.) a soluble radio-opaque material, and b.) releasing said occludant precursor composition at said selected site to form said occlusion mass.
16. The method of claim 15 wherein the introducing step is carried out using a tubular member.
17. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
18. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
19. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
20. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
22
21. The method of claim 15 wherein the composition contains between 7.5 and 30%(wf) of partially hydrolyzed polyvinylacetate.
22. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises ethanol.
23. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
24. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
25. The method of claim 24 wherein the aqueous ethanolic solution contains 45- 55% ethanol.
26. [cancelled]
27. The method of claim 15 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
28. The method of claim 15 wherein the radio-opaque material comprises iopromide.
23
29. The method of claim 15 wherein the radio-opaque material comprises metrizamide.
30. The method of claim 15 wherein the tubular member is passed into the portal vein proximal of the liver.
31. (new) An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, and b.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
32. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
33. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
34. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
35. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the ranee of 2.3 to 5.6.
24
36. (new) The occludant precursor composition of claim 35 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
37. (new) The occludant precursor composition of claim 31 further comprising a radio-opaque material.
38. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises a material selected from the group consisting of iopromide, metrizamide, and mixtures and solutions thereof.
39. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises iopromide.
40. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises metrizamide.
41. (new) A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate, and ii.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol, and b.) releasing said occludant precursor composition to form said occlusion mass.
42. (new) The method of claim 41 wherein the introducing step is carried out using a tubular member.
25
43. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
44. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100,000.
45. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
46. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
47. (new) The method of claim 41 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
48. (new) The method of claim 41 wherein the composition further comprises a radio-opaque material.
49. (new) The method of claim 48 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide. and mixtures and solutions thereof.
50. (new) The method of claim 48 wherein the radio-opaque material comprises iopromide.
26
51. (new) The method of claim 48 wherein the radio-opaque material comprises metrizamide.
52. (new) The method of claim 41 wherein the tubular member is passed into the portal vein proximal of the liver.
27 STATEMENT UNDER ARTICLE 19
This in response to the International Search Report mailed 3/3/98. In this Amendment, claims 1 1 and 26 have been cancelled and new claims 31 through 52 have been added. Consequently, claims 1 -10, 12-25. and 27-52 are under consideration. Reconsideration is requested.
28
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97912731A EP0934086B1 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
| JP51855298A JP3804071B2 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agent containing partially hydrolyzed polyvinyl acetate |
| DE69735534T DE69735534T2 (en) | 1996-10-17 | 1997-10-15 | LIQUID EMBOLIZING AGENTS OF PARTIALLY HYDROLYZED POLYVINYL ACETATE |
| AU49842/97A AU4984297A (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
| US09/291,853 US6160025A (en) | 1996-10-17 | 1999-04-14 | Liquid embolic agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/734,442 | 1996-10-17 | ||
| US08/734,442 US5925683A (en) | 1996-10-17 | 1996-10-17 | Liquid embolic agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/734,442 Continuation-In-Part US5925683A (en) | 1996-10-17 | 1996-10-17 | Liquid embolic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/291,853 Continuation US6160025A (en) | 1996-10-17 | 1999-04-14 | Liquid embolic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998016265A1 WO1998016265A1 (en) | 1998-04-23 |
| WO1998016265B1 true WO1998016265B1 (en) | 1998-06-18 |
Family
ID=24951721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/018582 WO1998016265A1 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5925683A (en) |
| EP (1) | EP0934086B1 (en) |
| JP (1) | JP3804071B2 (en) |
| AU (1) | AU4984297A (en) |
| DE (1) | DE69735534T2 (en) |
| WO (1) | WO1998016265A1 (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063070A (en) | 1997-08-05 | 2000-05-16 | Target Therapeutics, Inc. | Detachable aneurysm neck bridge (II) |
| EP1003422B1 (en) | 1997-08-05 | 2006-06-14 | Boston Scientific Limited | Detachable aneurysm neck bridge |
| US6146373A (en) * | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
| US6511468B1 (en) | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
| AU5905599A (en) | 1998-09-04 | 2000-03-27 | Boston Scientific Limited | Detachable aneurysm neck closure patch |
| FR2784580B1 (en) | 1998-10-16 | 2004-06-25 | Biosepra Inc | POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME |
| AU6058000A (en) * | 1999-07-12 | 2001-01-30 | Scimed Life Systems, Inc. | Liquid based vaso-occlusive compositions |
| US6346098B1 (en) | 2000-03-07 | 2002-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and kits for locally administering an active agent to an interstitial space of a host |
| DE60130544T2 (en) | 2000-03-13 | 2008-06-26 | Biocure, Inc. | EMBOLIC COMPOSITIONS |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| DE01918975T1 (en) * | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Microspheres for active embolization |
| US6729356B1 (en) * | 2000-04-27 | 2004-05-04 | Endovascular Technologies, Inc. | Endovascular graft for providing a seal with vasculature |
| US6658288B1 (en) | 2000-05-05 | 2003-12-02 | Endovascular Technologies, Inc. | Apparatus and method for aiding thrombosis through the application of electric potential |
| DE10117099A1 (en) * | 2000-08-02 | 2002-02-21 | Aesculap Ag & Co Kg | Medical technology product, process for its production and provision for surgery |
| US20030180251A1 (en) * | 2000-08-02 | 2003-09-25 | Volker Friedrich | Medical technical product, method for producing the same and providing the same for surgery |
| EP1381420A2 (en) * | 2001-04-26 | 2004-01-21 | Christopher H. Porter | Method and apparatus for delivering materials to the body |
| US20030004568A1 (en) * | 2001-05-04 | 2003-01-02 | Concentric Medical | Coated combination vaso-occlusive device |
| EP1392182A1 (en) * | 2001-05-04 | 2004-03-03 | Concentric Medical | Hydrogel vaso-occlusive device |
| AU2002305401A1 (en) * | 2001-05-04 | 2002-11-18 | Concentric Medical | Hydrogel filament vaso-occlusive device |
| US6685745B2 (en) | 2001-05-15 | 2004-02-03 | Scimed Life Systems, Inc. | Delivering an agent to a patient's body |
| US7687053B2 (en) | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| US20030050635A1 (en) * | 2001-08-22 | 2003-03-13 | Csaba Truckai | Embolization systems and techniques for treating tumors |
| US6911219B2 (en) * | 2001-09-27 | 2005-06-28 | Surgica Corporation | Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them |
| WO2003037191A1 (en) * | 2001-10-26 | 2003-05-08 | Concentric Medical | Device for vaso-occlusion |
| US7341716B2 (en) * | 2002-04-12 | 2008-03-11 | Boston Scientific Scimed, Inc. | Occlusive composition |
| CA2503949C (en) * | 2002-10-29 | 2012-10-23 | Toray Industries, Inc. | Embolization material |
| HUP0203719A2 (en) * | 2002-10-31 | 2007-09-28 | Stepan Dr Gudak | Polyuretan composition for fillin blood vessels and method of aplication of it |
| US20040115164A1 (en) * | 2002-12-17 | 2004-06-17 | Pierce Ryan K. | Soft filament occlusive device delivery system |
| WO2004080503A1 (en) * | 2003-03-07 | 2004-09-23 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels comprising high levels of contrast agent |
| US20050209674A1 (en) * | 2003-09-05 | 2005-09-22 | Kutscher Tuvia D | Balloon assembly (V) |
| US20050090804A1 (en) * | 2003-10-22 | 2005-04-28 | Trivascular, Inc. | Endoluminal prosthesis endoleak management |
| US20050283182A1 (en) * | 2004-06-21 | 2005-12-22 | Concentric Medical, Inc. | Systems and methods for intraluminal delivery of occlusive elements |
| KR20140090270A (en) | 2005-05-09 | 2014-07-16 | 바이오스피어 메디칼 에스.에이. | Compositions and methods using microspheres and non-ionic contrast agents |
| US8545530B2 (en) * | 2005-10-19 | 2013-10-01 | Pulsar Vascular, Inc. | Implantable aneurysm closure systems and methods |
| CA2625826C (en) * | 2005-10-19 | 2014-08-05 | Pulsar Vascular, Inc. | Methods and systems for endovascularly clipping and repairing lumen and tissue defects |
| WO2007090127A2 (en) | 2006-01-30 | 2007-08-09 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| WO2007090130A2 (en) * | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
| US7442105B2 (en) * | 2006-05-05 | 2008-10-28 | Freleng Safety Products, Llc | Personal visibility marker |
| US9642693B2 (en) * | 2007-04-13 | 2017-05-09 | W. L. Gore & Associates, Inc. | Medical apparatus and method of making the same |
| US20080255678A1 (en) * | 2007-04-13 | 2008-10-16 | Cully Edward H | Medical apparatus and method of making the same |
| US9717584B2 (en) * | 2007-04-13 | 2017-08-01 | W. L. Gore & Associates, Inc. | Medical apparatus and method of making the same |
| CN103976770B (en) | 2008-09-05 | 2017-04-12 | 帕尔萨脉管公司 | Systems and methods for supporting or occluding a physiological opening or cavity |
| WO2010062678A2 (en) * | 2008-10-30 | 2010-06-03 | David Liu | Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same |
| ES2922979T3 (en) | 2009-09-04 | 2022-09-22 | Pulsar Vascular Inc | Systems to enclose an anatomical opening |
| KR102018035B1 (en) | 2011-06-03 | 2019-09-05 | 펄사 배스큘라, 아이엔씨. | Aneurysm devices with additional anchoring mechanisms and associated systems and methods |
| WO2012167150A1 (en) | 2011-06-03 | 2012-12-06 | Pulsar Vascular, Inc. | Systems and methods for enclosing an anatomical opening, including shock absorbing aneurysm devices |
| US9119625B2 (en) | 2011-10-05 | 2015-09-01 | Pulsar Vascular, Inc. | Devices, systems and methods for enclosing an anatomical opening |
| JP6411331B2 (en) | 2012-05-10 | 2018-10-24 | パルサー バスキュラー インコーポレイテッド | Aneurysm device with coil |
| CN102764456B (en) * | 2012-07-24 | 2014-10-15 | 上海交通大学 | Vascular occlusive agent, application thereof and preparation method |
| CN111840265B (en) * | 2019-04-29 | 2023-06-16 | 李学义 | Ethanol hardener and application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2160503A (en) * | 1936-02-14 | 1939-05-30 | Chemische Forschungs Gmbh | Blood stancher |
| US2657201A (en) * | 1949-11-25 | 1953-10-27 | Du Pont | Controlled, heterogeneous hydrolysis of polymeric esters |
| DE2031724C3 (en) * | 1969-06-27 | 1979-06-28 | Nyegaard & Co. A/S., Oslo | N-substituted triiodobenzamides or iodomethanesulfonamides, processes for their preparation and radiological compositions |
| DE2909439A1 (en) * | 1979-03-08 | 1980-09-18 | Schering Ag | NEW NON-ionic x-ray contrast agents |
| US4631188A (en) * | 1983-08-31 | 1986-12-23 | S.K.Y. Polymers, Ltd. (Kingston Technologies) | Injectable physiologically-acceptable polymeric composition |
| US4739768B2 (en) * | 1986-06-02 | 1995-10-24 | Target Therapeutics Inc | Catheter for guide-wire tracking |
| GB8900376D0 (en) * | 1989-01-09 | 1989-03-08 | Nycomed As | Iodinated esters |
| US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
| US5690666A (en) * | 1992-11-18 | 1997-11-25 | Target Therapeutics, Inc. | Ultrasoft embolism coils and process for using them |
| US5443454A (en) * | 1992-12-09 | 1995-08-22 | Terumo Kabushiki Kaisha | Catheter for embolectomy |
| WO1996004954A1 (en) * | 1994-08-17 | 1996-02-22 | Boston Scientific Corporation | Implant, and method and device for inserting the implant |
| US5749894A (en) * | 1996-01-18 | 1998-05-12 | Target Therapeutics, Inc. | Aneurysm closure method |
| US5702361A (en) * | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
-
1996
- 1996-10-17 US US08/734,442 patent/US5925683A/en not_active Expired - Lifetime
-
1997
- 1997-10-15 AU AU49842/97A patent/AU4984297A/en not_active Abandoned
- 1997-10-15 WO PCT/US1997/018582 patent/WO1998016265A1/en active IP Right Grant
- 1997-10-15 JP JP51855298A patent/JP3804071B2/en not_active Expired - Fee Related
- 1997-10-15 DE DE69735534T patent/DE69735534T2/en not_active Expired - Lifetime
- 1997-10-15 EP EP97912731A patent/EP0934086B1/en not_active Expired - Lifetime
-
1999
- 1999-04-14 US US09/291,853 patent/US6160025A/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998016265B1 (en) | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate | |
| DE69826452T2 (en) | LOCAL SPECIFIC PROTEIN MODIFICATION | |
| EP2347770B2 (en) | Process for producing an injectable pharmaceutical preparation | |
| US4317815A (en) | LH-RH Antagonists | |
| CA2198917A1 (en) | Sustained release of peptides from pharmaceutical compositions | |
| CH619614A5 (en) | ||
| CH629475A5 (en) | METHOD FOR PRODUCING POLYPEPTIDES. | |
| ATE49886T1 (en) | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND PROCESSES FOR THEIR MANUFACTURE. | |
| CA2212856A1 (en) | Benzopyran-containing compounds and method for their use | |
| EP0378255A3 (en) | 2-aminopyrimidinone derivatives | |
| TW329386B (en) | Cough medicine | |
| IE881017L (en) | Novel 2ß-morpholino-androstane derivatives and processes for¹their preparation | |
| HUT64518A (en) | Process for producing 4-phenyl-piperidine-4-carbixamide derivatives and pharmaceutical preparatives containing these compounds as active agents | |
| CA2085469A1 (en) | Water-soluble polypeptides with strong affinity for .alpha. and .beta. interferons | |
| CA2381461A1 (en) | Lhrh antagonists having improved solubility properties | |
| WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
| DE69001734T2 (en) | AMUSULOSIN PREPARATION TO BE USED EXTERNALLY. | |
| EP0383346A3 (en) | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | |
| IE51657B1 (en) | Lh-rh antagonists | |
| WO1999005103A3 (en) | 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent | |
| CA2249753A1 (en) | Improved process for the synthesis of alkylpolyglucosides | |
| ATE30231T1 (en) | 3-BETA-(3'-(CARBOXYPROPIONYLOXY))-URSA-9(11),12 DIENE-28-CARBONIC ACID AND ITS SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS. | |
| US4368138A (en) | Water soluble thymidine derivative | |
| US4389414A (en) | Prostaglandin compositions | |
| EP0387090A3 (en) | Steroid derivatives,processes for their preparation and pharmaceutical compositions thereof |